Thoracic SMARCA2-deficient But SMARCA4-preserved Tumors With Undifferentiated Morphology Combined With Claudin-4 Negativity

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a recently recognized tumor characterized by inactivation of SMARCA4, a SWItch/Sucrose NonFermentable chromatin remodeler, detectable by immunohistochemistry. SMARCA4-UT shows undifferentiated or rhabdoid morphology with claudin-4 negativity. However, thoracic undifferentiated tumors with the same histologic features as SMARCA4-UTs but a preserved SMARCA4 expression have so far been underrecognized. We herein report 3 cases of thoracic undifferentiated tumors with isolated loss of SMARCA2 but retained expression of SMARCA4 and SMARCB1. The present tumors were found in 2 men and 1 woman, 40 to 50 years old. All patients were heavy smokers (≥20 pack-years). The tumors were generally large masses located in the mediastinum, lung>chest wall, or lung and composed of relatively monotonous, round to epithelioid cells with variably rhabdoid cells. Immunohistochemically, the tumors showed claudin-4 negativity with variable expression of cytokeratin. All cases showed highly aggressive clinical behavior with overall survival of 2 to 10 months. These SMARCA2-deficient tumors with preserved SMARCA4 expression appeared to be clinicopathologically indistinguishable from SMARCA4-UTs, except for in their SMARCA4 status. This variant may expand the spectrum of SWItch/Sucrose NonFermentable–deficient undifferentiated tumors of the thoracic region beyond SMARCA4-UT.

[1]  G. Pelosi,et al.  SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  A. Hartmann,et al.  Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases , 2021, Virchows Archiv.

[3]  F. Le Loarer,et al.  SWI/SNF-deficient thoraco-pulmonary neoplasms. , 2021, Seminars in diagnostic pathology.

[4]  J. Goldblum,et al.  SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction. , 2020, The American journal of surgical pathology.

[5]  E. Sasaki,et al.  AKT1 Mutations in Peripheral Bronchiolar Papilloma , 2020, The American journal of surgical pathology.

[6]  M. Tsuboi,et al.  Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden. , 2019, Lung cancer.

[7]  David R. Jones,et al.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  J. Siedlecki,et al.  BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex—a tumour suppressor or tumour-promoting factor? , 2019, Epigenetics & Chromatin.

[9]  A. Cesne,et al.  Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Blay,et al.  SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses , 2019, The American journal of surgical pathology.

[11]  Y. Yatabe,et al.  Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion , 2018, Histopathology.

[12]  Y. Iwamoto,et al.  SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma , 2018, The American journal of surgical pathology.

[13]  A. Roden,et al.  SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior , 2017, Modern Pathology.

[14]  Simion I. Chiosea,et al.  SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity , 2017, The American journal of surgical pathology.

[15]  I. Feldman,et al.  Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models , 2017, Molecular Cancer Therapeutics.

[16]  T. Kohno,et al.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities , 2017, Modern Pathology.

[17]  A. Warth,et al.  SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. , 2017, Annals of diagnostic pathology.

[18]  S. Croce,et al.  Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology , 2017, Histopathology.

[19]  C. Fletcher,et al.  Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas , 2017, Modern Pathology.

[20]  A. Hartmann,et al.  SWI/SNF Complex–deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2 , 2016, The American journal of surgical pathology.

[21]  G. Bepler,et al.  SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[22]  N. Girard,et al.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.

[23]  N. Schultz,et al.  Recurrent SMARCA4 mutations in small cell carcinoma of the ovary , 2014, Nature Genetics.

[24]  R. Siebert,et al.  Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type , 2014, Nature Genetics.

[25]  Jason J. Corneveaux,et al.  Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 , 2014, Nature Genetics.

[26]  G. Crabtree,et al.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy , 2013, Nature Genetics.

[27]  S. Ishikawa,et al.  Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features , 2013, Cancer science.

[28]  P. D. Dal Cin,et al.  Loss of INI1 Expression is Characteristic of Both Conventional and Proximal-type Epithelioid Sarcoma , 2009, The American journal of surgical pathology.

[29]  D. Reisman,et al.  The reversible epigenetic silencing of BRM: implications for clinical targeted therapy , 2007, Oncogene.

[30]  Stuart H. Orkin,et al.  The SWI/SNF complex — chromatin and cancer , 2004, Nature Reviews Cancer.

[31]  B. Emerson,et al.  Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. , 2003, Molecular cell.